Status:
COMPLETED
Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing PEP
Lead Sponsor:
Air Force Military Medical University, China
Conditions:
Healthy
Eligibility:
All Genders
18-90 years
Brief Summary
Rectal indomethacin and pancreatic duct (PD) stenting (PDS) are recommended for the prevention of post-ERCP pancreatitis (PEP). However, the effects of the combination of the two methods on preventing...
Eligibility Criteria
Inclusion
- Patients underwent diagnostic or therapeutic ERCP
- With native papilla
- With difficult cannulation (cannulation time \>10min or cannulation attempts \>5 times or inadvertently PD cannulation ≥1)
- Receiving post-ERCP rectal indomethacin
Exclusion
- Patients with indications of PD cannulation
- No attempt of cannulation due to inaccessible papilla
- Non-difficult cannulation
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
664 Patients enrolled
Trial Details
Trial ID
NCT04340687
Start Date
January 1 2020
End Date
March 1 2020
Last Update
April 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, China, 710032